Acquisition Deadline Looms for HilleVax Shareholders

The future of clinical-stage pharmaceutical company HilleVax will be determined on Monday as the takeover bid from biotechnology specialist XOMA Royalty expires. This pivotal moment forces investors to evaluate what the proposed transaction genuinely offers.

Recent quarterly figures highlight a significant strategic shift for HilleVax. For the first half of 2025, the company reported a substantially reduced net loss of $11.3 million, a dramatic improvement from the $87.5 million loss recorded during the same period the previous year. This positive change was driven primarily by a steep reduction in research and development expenditures, which fell to $3.3 million from $52.6 million, alongside lower general and administrative costs. With a solid cash position of $159.5 million, the company enters this transaction from a position of financial strength.

Final... Read more...